HYDROmorphone
Trade name
Dilaudid, Dilaudid-HP, Hydromorphone-hameln, Hydromorphone-hameln-HP, Hydromorphone Juno, Hydromorphone Juno-HP, Hydromorphone Juno-XHP, Medsurge Hydromorphone, Medsurge Hydromorphone HP
Strength
2 mg/mL (volume: 1 mL)
10 mg/mL (volume: 1 mL, 5 mL)
50 mg/mL (volume: 1 mL)
IV administration
2 mg/mL or 10 mg/mL strength: Use undiluted or dilute to a convenient volume.
50 mg/mL strength: Must dilute to a convenient volume before use.
Give over at least 2 minutes or by continuous infusion.
Refer to relevant local guidelines for more information.
Other routes of administration
IM: Suitable, but not the preferred route as variable absorption and pain may occur.
SC: Suitable.
Compatible IV fluids
Glucose 5%
Sodium chloride 0.9%
Hydromorphone 0.08 mg/mL or weaker:
Glucose 5% and sodium chloride 0.9%
Glucose 5% and sodium chloride 0.45%
Hartmann’s
Ringer’s
Y-site only:
Potassium chloride 20 mmol/L
Y-site only and hydromorphone 2 mg/mL or weaker:
Plasma-Lyte 148
Additional information
Take care with selecting products as High Potency (HP) and Extra High Potency (XHP) formulations are intended for use in opioid-tolerant patients only.
Concomitant use of CNS depressants (e.g. parenteral benzodiazepines, IM olanzapine) increases risk of respiratory depression, sedation, coma and death.
Monitor respiratory rate, sedation and blood pressure.
Rapid administration has been associated with an increase in side effects, especially respiratory depression and hypotension.
Taper the infusion slowly when discontinuing treatment; abrupt discontinuation may cause withdrawal and uncontrolled pain.
Solution should be clear and colourless or slightly yellow. If the solution is darker than pale yellow, it should not be used.
Protect from light during storage and infusion.